Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
643 Results for "
systemically
" in MedChemExpress (MCE) Product Catalog:
Products (643)
643 Results for "systemically" in MCE Product Catalog:
Cat. No.: HY-183308
Antifungal agent-161 (Compound 7) is an Antifungal agent. Antifungal agent-161 potently inhibits Candida albicans ATCC 36082 (with a MIC of 1.32 μM) and Candida glabrata ATCC 2001 (with a MIC of 1.66 μM). Antifungal agent-161 reduces fungal loads in infected mice and eliminates Candida albicans and Candida glabrata infections. Antifungal agent-161 can be used for the research of candidiasis .
Cat. No.: HY-184076
CAS No.: 2978107-47-8
Research Areas:
Ibrilparant is a LPA1 receptor antagonist with an IC50 of 0.00753 μM. Ibrilparant exhibits LPA1 calcium flux antagonistic activity, with an IC50 of 3.02 nM. Ibrilparant can be used in research related to various diseases such as cancer and inflammatory diseases .
Cat. No.: HY-P11422
Target:
Research Areas:
Cat. No.: HY-120657R
CAS No.: 1481636-31-0
Target:
Cat. No.: HY-120657S
CAS No.: 2704278-85-1
Cat. No.: HY-120657S1
CAS No.: 2748208-06-0
Cat. No.: HY-121151S2
Synonyms: (±)-Amethopterin-13C,d3 disodium; (±)-CL14377-13C,d3 disodium; (±)-WR19039-13C,d3 disodium
Cat. No.: HY-144026S
CAS No.: 1809222-43-2
Cat. No.: HY-164288
CAS No.: 2287331-29-5
Synonyms: TDI-006570
Target:
Research Areas:
TDI-6570 (TDI-006570) is a blood-brain barrier-permeable, orally active cGAS inhibitor with an IC50 of 1.64 μM. TDI-6570 exhibits high gastrointestinal absorption and a long brain half-life in mice, and shows no toxicity to primary neurons. By inhibiting the cGAS-STING-IFN signaling pathway, TDI-6570 reduces STING levels and the activation of TBK1, blocks double-stranded DNA-induced cGAS activation and downstream interferon-stimulated gene expression, thereby reducing tau protein spread and improving synaptic loss. TDI-6570 reverses memory deficits, increases the amplitude of long-term potentiation, enhances the MEF2C transcriptional network, restores PSD-95 and vGAT punctate structures, and significantly improves cognitive resilience. TDI-6570 can be applied to the research of Alzheimer's disease, Parkinson's disease, systemic lupus erythematosus, as well as various central nervous system and autoimmune diseases .
Cat. No.: HY-P990955
CAS No.: 2839652-75-2
Synonyms: ADX-097
Target:
Research Areas:
Cat. No.: HY-P991510
Target:
Research Areas:
Cat. No.: HY-112448
CAS No.: 918870-43-6
Target:
Research Areas:
Lck-IN-6 (Compound 12g) is a Lck inhibitor with an IC50 of 3 nM. Lck-IN-6 inhibits the production of IL-2. Lck-IN-6 can be used in the research of rheumatoid arthritis and inflammatory bowel disease .
Cat. No.: HY-164919
CAS No.: 2847102-44-5
Synonyms: XMT-2056
Research Areas:
Calotatug ginistinag (XMT-2056) is an antibody-drug conjugate (ADC) targeting HER2, linked to a payload composed of XMT-1519 conjugate-1 (HY-148067) and STING agonist-20 (HY-148068). Calotatug ginistinag activates the STING signaling pathway in tumor cells and tumor-resident immune cells, induces the production of type I interferons and cytokines (CXCL10, IFN-β, IL-6, TNF-α, triggers innate anti-tumor immune responses, and exerts a bystander effect. Calotatug ginistinag exhibits efficacy against HER2-expressing cancer cells in co-culture with PBMCs. Calotatug ginistinag induces tumor regression and reduces systemic inflammation in various tumor models. Combination treatment with Calotatug ginistinag, Trastuzumab (HY-P9907) and T-DXd (HY-138298) yields benefits. Calotatug ginistinag can be used in studies related to HER2-expressing solid tumors such as breast cancer, gastric cancer and ovarian cancer .
Target:
Research Areas:
DSPE-PEG2000-Biotin is a biotin-labeled PEG derivative composed of phospholipid (DSPE), a hydrophilic polyethylene glycol chain (PEG2000) and a biotin tag. DSPE-PEG2000-Biotin is widely used in scientific research for constructing targeted liposomes, micelles and lipid nanoparticles for drug delivery and cell binding experiments .
Cat. No.: HY-140736A
CAS No.: 385437-57-0
Target:
Research Areas:
DSPE-PEG1000-Biotin is a biotin-labeled PEG derivative composed of phospholipid (DSPE), a hydrophilic polyethylene glycol chain (PEG1000) and a biotin tag. DSPE-PEG1000-Biotin is widely used in scientific research for constructing targeted liposomes, micelles and lipid nanoparticles for drug delivery and cell binding experiments .
Cat. No.: HY-140736B
CAS No.: 385437-57-0
Target:
Research Areas:
DSPE-PEG5000-Biotin is a biotin-labeled PEG derivative composed of phospholipid (DSPE), a hydrophilic polyethylene glycol chain (PEG5000) and a biotin tag. DSPE-PEG5000-Biotin is widely used in scientific research for constructing targeted liposomes, micelles and lipid nanoparticles for drug delivery and cell binding experiments .
Cat. No.: HY-L251
93 compounds
Ionizable lipids are a class of specialized, functional lipid molecules with pH-sensitive charge characteristics. They are primarily divided into two major categories: ionizable cationic lipids and ionizable anionic lipids, though the term typically specifies ionizable cationic lipids within the biomedical field. Structurally, these lipids consist of an ionizable hydrophilic headgroup, a biodegradable linker, and hydrophobic tails. Their primary application is serving as the key delivery vehicle in lipid nanoparticles (LNPs) to encapsulate negatively charged nucleic acid macromolecules, such as mRNA vaccines, siRNA therapeutics, and CRISPR gene-editing components. In a physiological, neutral environment, they remain electrically neutral to minimize systemic toxicity and prolong circulation time. Upon entering the acidic microenvironment of cellular endosomes, however, they undergo protonation to become positively charged, thereby inducing membrane fusion and enabling the highly efficient intracellular release of the nucleic acid cargo. Consequently, they serve as the technological cornerstone for bringing nucleic acid therapies into clinical application.
To accelerate the translational process of cutting-edge nucleic acid drugs, MCE has meticulously constructed an ionizable lipid compound library containing 93 high-performance molecules, aiming to provide researchers and pharmaceutical professionals with a high-throughput, multi-dimensional lipid screening platform.
306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies .
Cat. No.: HY-185379
CAS No.: 3106554-00-8
Target:
Research Areas:
STING antagonist-3 is a potent STING antagonist with an IC50 of 2.3 nM against human wild-type STING. STING antagonist-3 inhibits human wild-type STING and the gain-of-function STING mutants N154S and V155M. STING antagonist-3 suppresses IFN‑α2a production in stimulated human whole blood. STING antagonist-3 inhibits IP-10 production in activated human dermal microvascular endothelial cells (HMVEC-d). STING antagonist-3 can be used for the research of autoimmune diseases, autoinflammatory diseases, interferonopathies, and fibrotic disorders .
Cat. No.: HY-L076
641 compounds
Drug-induced liver injury (DILI; also known as drug-induced hepatotoxicity) is caused by medications (prescription or OTC), herbal and dietary supplements (HDS), or other xenobiotics that result in abnormalities in liver tests or in hepatic dysfunction that cannot be explained by other causes. Drugs are an important cause of liver injury. Drug-induced hepatic injury is the most common reason cited for withdrawal of an approved drug.
DILI is thought to occur via several different mechanisms. Among these are direct impairment of the structural (e.g., mitochondrial dysfunction) and functional integrity of the liver; production of a metabolite that alters hepatocellular structure and function; production of a reactive drug metabolite that binds to hepatic proteins to produce new antigenic drug-protein adducts, which are targeted by hosts’ defenses (the hapten hypothesis); and initiation of a systemic hypersensitivity response (i.e., drug allergy) that damages the liver.
MCE Drug-induced Liver Injury (DILI) Compound Library contains a unique collection of 641 hepatotoxicity causing compounds and is a powerful tool to research DILI and other drug toxicities. This library can be used to understand the mechanisms of DILI, identify biomarkers for early DILI prediction, and allow timely recognition during drug development, thus finally achieving successful DILI prevention and assessment in the pre-marketing phase.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
